0001566044-26-000002
SEC filingVYNE Therapeutics Inc. reported a net loss of $26.5 million for fiscal year 2025, a significant improvement from a net loss of $39.8 million in 2024. Total revenues were minimal at $570K, while operating expenses totaled $30.3M, primarily driven by research and development ($19.2M) and general and administrative ($11.1M) costs. The company's cash position improved with cash and cash equivalents ending at $30.7M, supported by $37.4M in net cash provided by investing activities from marketable securities transactions. Key forward-looking developments include the discontinuation of the repibresib gel Phase 2b trial in July 2025 after it failed to meet primary and key secondary endpoints, and the pending merger with Yarrow which may impact the company's net operating loss carryforwards.
VYNE Therapeutics Inc. reported a net loss of $26.5 million for fiscal year 2025, representing a significant improvement from the $39.8 million net loss reported in 2024. Total revenues were minimal at $570,000, while operating expenses totaled $30.3 million, consisting of $19.2 million in research and development and $11.1 million in general and administrative expenses. The company reported an operating loss of $29.7 million, which was partially offset by other income of $3.0 million. Loss from continuing operations was $26.7 million, with a small positive contribution of $253,000 from discontinued operations. The company ended the year with $30.7 million in cash and cash equivalents, representing an increase of $4.1 million from the prior year.
The company generated minimal revenue of $570,000 during fiscal year 2025. No segment breakdown or geographic revenue mix was disclosed in the provided document. The company's primary focus remains on research and development activities rather than commercial operations. The document indicates the company is in the clinical development stage with product candidates including repibresib and VYN202, though the repibresib gel Phase 2b trial was discontinued in July 2025 after failing to meet primary and key secondary endpoints.
The company operates at a significant loss with negative margins across all profitability measures. With minimal revenue of $570,000 and total operating expenses of $30.3 million, the operating margin is deeply negative. Research and development expenses of $19.2 million represent the largest component of operating costs, reflecting the company's focus on clinical development. General and administrative expenses of $11.1 million support corporate operations. The company's cost structure reflects its status as a clinical-stage biopharmaceutical company with no commercial products generating substantial revenue.
Net cash used in operating activities was $33.1 million, primarily reflecting the net loss of $26.5 million adjusted for non-cash share-based compensation expense of $2.3 million. Net cash provided by investing activities was $37.4 million, consisting of $68.3 million from the sale and maturity of marketable securities offset by $30.9 million for purchases of marketable securities. The balance sheet shows total assets of $30.2 million, including $24.0 million in cash and cash equivalents and $5.0 million in marketable securities. Total liabilities were $2.4 million, resulting in shareholders' equity of $27.8 million. The company had federal net operating loss carryforwards of $332.1 million and state net operating loss carryforwards of $94.2 million as of December 31, 2025.
The company faces several forward-looking challenges and opportunities. The pending merger with Yarrow will result in an ownership change that may limit the company's ability to utilize its net operating loss carryforwards. The company discontinued the repibresib gel Phase 2b trial in July 2025 after it failed to meet primary and key secondary endpoints. If the merger is not consummated, the company may pursue other strategic alternatives including in-licensing or acquiring additional product candidates. The company is not currently in compliance with Nasdaq's minimum bid price requirement and has until March 10, 2026 to regain compliance. Risk factors include dependence on the success of clinical trials, regulatory approvals, competition, intellectual property protection, and the ability to raise additional capital.